Opinion

Video

Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

The panel reviews results from the ATTEND and DUO-E trials in advanced endometrial cancer, suggesting pembrolizumab remains the standard for the dMMR patient subset while combinations with PARP inhibitors may improve outcomes in pMMR.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.